Marex Group’s Prelude Therapeutics PRLD Stock Holding History

Marex Group’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-56,270	Closed	-$43.2K	–	869
2025 Q1	$43.2K	Buy	+56,270	New	+$52.5K	﹤0.01%	646

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Marex Group's PRLD Position: Q2 2025 in Review

Marex Group sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 56,270 shares — an estimated $43.2K sold.

Marex Group first reported a position in PRLD in Q1 2025 and held it in 1 quarter. The position peaked at $43.2K in Q1 2025. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

Marex Group reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
Marex Group sold 56,270 Prelude Therapeutics shares in Q2 2025, an estimated $43.2K.
Marex Group first reported a position in Prelude Therapeutics in Q1 2025 and held it in 1 quarter.
Marex Group's Prelude Therapeutics position peaked at $43.2K in Q1 2025.
50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on Marex Group's 13F filing for Q2 2025, filed 19 Aug 2025.